ASH: With Yescarta leading in earlier-line lymphoma, Bristol Myers keeps the heat on with full data for Breyanzi

Kicking off this weekend’s #ASH21, Gilead’s Kite and Bristol Myers Squibb have released competing data for their current-gen CAR-T drugs in second-line B cell lymphoma patients. It’s a heated contest to move these drugs into earlier lines of therapy, and Bristol Myers thinks these fuller data will keep the pressure…

...

Click to view original post